Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Jul 4;103(9):1679–1687. doi: 10.1111/j.1349-7006.2012.02339.x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2012 Japanese Cancer Association

Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.

PMC Copyright notice

Fig. 4 — Kaplan–Meier disease-free survival by different chemotherapy regimens. (A) all population, anthracycline-based and Taxane-based regimens were superior to classical cyclophosphamide, methotrexate, and 5-fluorouracil (5FU) (CMF) regimens for disease-free survival (DFS) in all populations, there was no difference between anthracycline-based and Taxane-based regimens (P = 0.026); (B) luminal A, there was no difference among three regimens (P = 0.095); (C) luminal B (high Ki-67); (D) luminal B (Her2/neu+); (E) Her2/neu+, anthracycline-based and Taxane-based regimens were superior to classical CMF regimens for DFS in luminal B (whether high Ki-67 or Her2/neu, also Her2/neu, P = 0.001), but there was no difference between anthracycline-based and Taxane-based regimens (P = 0.126); (F) triple negative breast cancer (TNBC), there was no difference among all three regimens (P = 0.089).